Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : The trend should regain control

10/23/2020 | 08:28am EDT
long trade
Target price hit
Entry price : 481$ | Target : 530$ | Stop-loss : 457$ | Potential : 10.19%
Shares in Thermo Fisher Scientific show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the $ 530.
Thermo Fisher Scientific : Thermo Fisher Scientific : The trend should regain control
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

  • The company returns high margins, thereby supporting business profitability.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 354.2 USD

  • Stock prices approach a strong long-term resistance in weekly data at USD 516.58.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company benefits from high valuations in earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

ę MarketScreener.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 35 646 M - -
Net income 2021 7 166 M - -
Net Debt 2021 12 736 M - -
P/E ratio 2021 29,5x
Yield 2021 0,18%
Capitalization 208 B 208 B -
EV / Sales 2021 6,19x
EV / Sales 2022 6,10x
Nbr of Employees 80 000
Free-Float 89,6%
Income Statement Evolution
Mean consensus BUY
Number of Analysts 24
Last Close Price 529,12 $
Average target price 554,79 $
Spread / Average Target 4,85%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Mark P. Stevenson Chief Operating Officer & Executive Vice President
Scott M. Sperling Independent Director
Sector and Competitors